{"id":"ornithine-aspartate-granule","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL446143","moleculeType":"Small molecule","molecularWeight":"132.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ornithine aspartate is a combination of the amino acids ornithine and aspartate that enhances ammonia detoxification through two pathways: ornithine facilitates ammonia removal via the urea cycle, while aspartate supports glutamine synthesis. This dual mechanism reduces circulating ammonia concentrations, which are elevated in liver disease and contribute to neurological dysfunction in hepatic encephalopathy.","oneSentence":"Ornithine aspartate reduces ammonia levels by promoting its incorporation into urea and glutamine synthesis, thereby improving hepatic encephalopathy symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:00.375Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic encephalopathy"},{"name":"Elevated blood ammonia levels in liver disease"}]},"trialDetails":[{"nctId":"NCT05042245","phase":"PHASE4","title":"The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2019-07-23","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":237},{"nctId":"NCT01847651","phase":"PHASE4","title":"Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-08","conditions":"Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Cirrhosis","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ornithine aspartate granule","genericName":"Ornithine aspartate granule","companyName":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","companyId":"xinhua-hospital-shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ornithine aspartate reduces ammonia levels by promoting its incorporation into urea and glutamine synthesis, thereby improving hepatic encephalopathy symptoms. Used for Hepatic encephalopathy, Hyperammonemia associated with liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}